Abstract No. 5013Indication: ovarian cancer Clinical Trial: Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer. Presentation Time: Sunday, June 6. Oral session. Notes: Women treated with NKTR-102 once ever 14 days reported a 47% response rate, while women treated with NKTR-102 once ever 21 days reported a 41% response rate, according to Thursday's research abstract. These reported response rates from 71 enrolled patients are higher than interim results from the same study reported last January.